RAC

3.31%

$1.61 race oncology ltd

Q8 - the other drug, brequinar, had widely varying dosing issues...

First 48 Last

Share
Profile

Follow
Waynecarey

276 Posts.

139

17/12/20

14:57

Post #: 49655039
Share

Originally posted by Phantom1: ↑

Hi all
A post as I had some time to spare. I posted a bit on RAC some months ago. I was one of the early investors. Please see earlier posts to expand on the following points. I made good money here and am very happy others did even better. The share price rise has been stellar. I am however a little concerned re the future.
1. company has done new preclinical work on an indication (breast cancer) that has already been in clinical studies. This implies to me that the earlier preclinical data has not been accepted as there was no need to repeat it. FTO component of study not powered so not helpful. We already knew Bisantrene works in preclinical breast cancer.
2. Doxorubicin costs around $100 per dose. Comparing Bisantrene to monoclonal or checkpoint inhibitor prices is not sensible. The price per dose of this drug will be very cheap.
3. there are other analogies of bisantrene and very similar cyclical structures being developed
4. If Bisantrene was going to be bought out as a chemo drug based on lowered side effects without another significant / pivotal trial being performed I don’t see why this has not already happened. Thus I see another pivotal (or several) trials needed if that is the catalyst
5. The company can not fund the trials needed with current funds. It needs to be bought out or raise significant money (as the share price is so high it would be a good time now)
6. I do not understand why good board members / original driver left recently.
7. The share price rise was based on the checkpoint inhibition mechanism of action seen in the COH paper. It was very good but it is not acting as a chemotherapy agent but rather an immunotherapy agent. This is the big advance in the story. However the mice were given activated T cells as well to get the response. Thus Car-t or another like tech is needed.
8. The other drug in the COH study that worked just as well finishes its phase 1/2a trial this month (27 patients). It is oral, does not need a central line placement and is cheap. Which drug would a big pharma take over? More variables here than price and ease of use to be sure but worth thinking about.
9. There has been an air of PR here that caused me to reflect.
Anyway, just ignore me, call me a troll-don’t really care. I truly hope everyone makes money here and I hope everyone has a great Christmas. A buy out seems to be the sensible way forward rather than further clinical development. I just thought that as any negative posts seem to be shot down so hard I would try a post that outlines the concerns some have in case anyone was interested.

Expand

Q8 - the other drug, brequinar, had widely varying dosing issues I believe.

RAC Price at posting: $1.91 Sentiment: Buy Disclosure: Held
4 Upvote

0 Great analysis

Reply

Top Stories

NVA

Nova locks in NASDAQ US market listing at a value of only US$3.3M as ASX gets quieter and quieter

Nine's staff strike as Paris Olympic coverage begins

ASX Market Open: ASX200 to rise for Friday session | July 26

HRZ

Horizon firms up ore reserve for Boorara ahead of FY25 Q1 development decision

MND

Monadelphous inks $200M contract with Woodside to help build Pluto LNG – but will it make Scarborough cheaper?

IGO

IGO kicks off earn-in copper drilling on-site Encounter's Yeneena play as it adopts new identity

Capital raisings wrap: Brainchip, Ovanti, Lake and VHM

RHK

Red Hawk upgrades Blacksmith with DSO mineral resource at the Eagle Deposit

TRP

Tissue Repairs soars nearly 32% on TGA approval for wound healing gel

MIN

MinRes jumps 5% as the company meets production guidance – depressed iron ore prices be damned

There are more pages in this discussion • 3 more messages in this thread...

First 48 Last

Add RAC (ASX) to my watchlist

(20min delay)
Last $1.61		Change -0.055(3.31%)		Mkt cap ! $273.4M

Open	High	Low	Value	Volume
$1.66	$1.68	$1.61	$271.5K	166.3K

Buyers (Bids)

No.	Vol.	Price($)
1	1996	$1.61

Sellers (Offers)

Price($)	Vol.	No.
$1.68	1305	2

View Market Depth

No.	Vol.	Price($)
2	4387	1.600
1	31000	1.590
1	10000	1.585
2	8233	1.560
4	15571	1.550

Price($)	Vol.	No.
1.690	585	1
1.700	17181	1
1.750	30400	2
1.755	990	1
1.820	1000	1

Last trade - 16.10pm 26/07/2024 (20 minute delay)

RAC (ASX) Chart

Q8 - the other drug, brequinar, had widely varying dosing issues...

Nova locks in NASDAQ US market listing at a value of only US$3.3M as ASX gets quieter and quieter

Nine's staff strike as Paris Olympic coverage begins

ASX Market Open: ASX200 to rise for Friday session | July 26

Horizon firms up ore reserve for Boorara ahead of FY25 Q1 development decision

Monadelphous inks $200M contract with Woodside to help build Pluto LNG – but will it make Scarborough cheaper?

IGO kicks off earn-in copper drilling on-site Encounter's Yeneena play as it adopts new identity

Capital raisings wrap: Brainchip, Ovanti, Lake and VHM

Red Hawk upgrades Blacksmith with DSO mineral resource at the Eagle Deposit

Tissue Repairs soars nearly 32% on TGA approval for wound healing gel

MinRes jumps 5% as the company meets production guidance – depressed iron ore prices be damned

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Q8 - the other drug, brequinar, had widely varying dosing issues...

Top Stories

Nova locks in NASDAQ US market listing at a value of only US$3.3M as ASX gets quieter and quieter

Nine's staff strike as Paris Olympic coverage begins

ASX Market Open: ASX200 to rise for Friday session | July 26

Horizon firms up ore reserve for Boorara ahead of FY25 Q1 development decision

Monadelphous inks $200M contract with Woodside to help build Pluto LNG – but will it make Scarborough cheaper?

IGO kicks off earn-in copper drilling on-site Encounter's Yeneena play as it adopts new identity

Capital raisings wrap: Brainchip, Ovanti, Lake and VHM

Red Hawk upgrades Blacksmith with DSO mineral resource at the Eagle Deposit

Tissue Repairs soars nearly 32% on TGA approval for wound healing gel

MinRes jumps 5% as the company meets production guidance – depressed iron ore prices be damned

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News